Pharmacokinetic Modeling of the “Nose-to-Brain” Pathway as Demonstrated by Intranasal Administration of Cannabidiol-Loaded Nanoparticles
Open Access
- 11 March 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (3) , 456
Abstract
Background/Objectives: Cannabidiol is a non-psychoactive substance that possesses properties suitable for the treatment of several disorders related to the central nervous system. However, successful administration of cannabidiol remains challenging due to low and variable bioavailability and potential adverse effects. Intranasal delivery of cannabidiol may help overcome these limitations, but the pharmacokinetics of such administration has not been fully established. Methods: Starch-based cannabidiol-loaded nanoparticles were used as carriers and were administered to rats via the intranasal route. Cannabidiol levels in plasma and the brain were examined at different time points and compared to cannabidiol levels in plasma and the brain following intravenous administration of cannabidiol solution for injection. Pharmacokinetic parameters were calculated for each delivery route, and a pharmacokinetic model was fitted for the intranasal administration. Results: Intranasal administration resulted in a bioavailability of 47.9%. Systemic absorption accounted for 44% of the absorbed drug, while 56% was absorbed by direct brain entry. Intranasal administration resulted in rapid brain penetration with a brain tmax of 10 min and demonstrated a brain bioavailability of 28.5% compared to bioavailability after intravenous bolus injection of cannabidiol solution. Conclusions: Intranasal administration of cannabidiol-loaded nanoparticles was found to be effective for the delivery of cannabidiol to the brain with significantly lower systemic exposure compared to intravenous administration. A proposed pharmacokinetic model was found to be appropriate in describing and predicting the disposition pathways following intranasal administration, especially when designing drug delivery systems for brain targeting.Keywords
This publication has 23 references indexed in Scilit:
- Cannabidiol and Liver Enzyme Level Elevations in Healthy AdultsJAMA Internal Medicine, 2025
- Intranasal drug delivery: The interaction between nanoparticles and the nose-to-brain pathwayAdvanced Drug Delivery Reviews, 2024
- Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of AdministrationPharmaceutical Research, 2023
- Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse modelEnvironmental Toxicology and Pharmacology, 2019
- Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administrationJournal of Controlled Release, 2017
- Cannabidiol: State of the art and new challenges for therapeutic applicationsPharmacology & Therapeutics, 2017
- PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft ExcelComputer Methods and Programs in Biomedicine, 2010
- Intranasal delivery to the central nervous system: Mechanisms and experimental considerationsJournal of Pharmaceutical Sciences, 2010
- Interactions ofΔ 11-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentographywith cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentographyCellular and Molecular Life Sciences, 1981
- Use of General Partial Fraction Theorem for Obtaining Inverse Laplace Transforms in Pharmacokinetic AnalysisJournal of Pharmaceutical Sciences, 1971